Ocular Therapeutix (OCUL) Misses Q1 EPS by 31c

Ocular Therapeutix (NASDAQ: OCUL) reported Q1 EPS of ($0.49), $0.31 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $14.77 million versus the consensus estimate of $15.36 million.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• Goldman Regional Director in US Adjusts List of Top Names
• General Mills (GIS) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY27 EPS Guidance
• Evercore ISI Upgrades XPO (XPO) to Outperform